Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery

May 20 (Reuters) - Bristol ⁠Myers Squibb said on Wednesday it is ⁠partnering with Anthropic to make its Claude AI model available to over 30,000 employees in an effort to accelerate the discovery, development and delivery of new medicines.

• Bristol said it ⁠will also leverage Claude ⁠Code, Anthropic's coding tool, and evaluate its use ⁠in research, drug development, manufacturing and other commercial and medical affairs.

• Drugmakers have ⁠announced a slew of deals for tools to unleash the promise of artificial intelligence.

• Many, including ⁠drugmaker Eli Lilly, which has partnered with leading chipmaker Nvidia, are betting AI can also improve the success ⁠rate of new drugs.

• "Most enterprise AI stops at the chatbot. The real prize is the untapped value still trapped behind decades ⁠of data silos, and this collaboration is how we reach it," said Greg Meyers, chief digital and technology officer at Bristol Myers.

• Agentic AI, which requires little human ⁠intervention, could increase clinical development productivity by about 35% to 45% over the next five years, consultancy McKinsey said last year.

(Reporting by Christy Santhosh in Bengaluru; Editing by Sahal Muhammed)